Cited 4 times in
Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double-blind, and placebo-controlled study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이민영 | - |
dc.contributor.author | 이병완 | - |
dc.date.accessioned | 2022-07-08T03:26:28Z | - |
dc.date.available | 2022-07-08T03:26:28Z | - |
dc.date.issued | 2022-06 | - |
dc.identifier.issn | 1462-8902 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/188853 | - |
dc.description.abstract | Aim: To investigate the effectiveness and safety of teneligliptin over placebo in patients with type 2 diabetes (T2D) inadequately controlled by triple therapy. Materials and methods: This trial was a prospective, multicentre, randomized, double-blind, placebo-controlled study. The 12-week double-blind period was followed by a 12-week, open-label clinical trial. One hundred patients with T2D who failed to achieve the glycaemic target (7.1% ≤ HbA1c ≤ 9.0%) with conventional triple oral antidiabetic drugs (OADs) of metformin, sulphonylurea, and sodium-glucose co-transporter-2 inhibitor were assigned randomly 1:1 into teneligliptin and placebo-teneligliptin groups. The primary endpoint was mean change in HbA1c level from baseline in each group at 12 weeks. Results: For a total of 99 patients (n = 51 for the teneligliptin group, and n = 48 for the placebo-teneligliptin group), the mean age and duration of diabetes were 60.7 and 13.6 years, respectively, and HbA1c was 7.8% at baseline. At 12 weeks, the teneligliptin group achieved a significant reduction in HbA1c from baseline (-0.9% ± 0.6%, P < .001), with an intergroup difference of -0.75% compared with the placebo group (95% CI [-0.99%, -0.51%], P < .001). At the end of the 24-week treatment period, both groups showed significant reductions in HbA1c level from baseline (placebo-teneligliptin group, -0.8% ± 0.6% [P < .001], teneligliptin group, -0.9% ± 0.6% [P < .001]), without significant intergroup difference (-0.17%, 95% CI [-0.41%, 0.07%], P = .156). There was no significant difference between the groups in the rate of adverse events (placebo-teneligliptin group, n = 3 [6.3%]; teneligliptin group, n = 11 [11.1%]; P = .550), and the safety profiles were favourable in both groups. Conclusions: The current study shows that teneligliptin could be a valid option as a fourth OAD for the treatment of patients with T2D inadequately controlled with a triple combination of OADs. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Wiley-Blackwell | - |
dc.relation.isPartOf | DIABETES OBESITY & METABOLISM | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Diabetes Mellitus, Type 2* / therapy | - |
dc.subject.MESH | Double-Blind Method | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Glycated Hemoglobin A / analysis | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypoglycemic Agents / adverse effects | - |
dc.subject.MESH | Metformin* / adverse effects | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Pyrazoles | - |
dc.subject.MESH | Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use | - |
dc.subject.MESH | Thiazolidines | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double-blind, and placebo-controlled study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Minyoung Lee | - |
dc.contributor.googleauthor | Woo-Je Lee | - |
dc.contributor.googleauthor | Jae Hyeon Kim | - |
dc.contributor.googleauthor | Byung-Wan Lee | - |
dc.identifier.doi | 10.1111/dom.14679 | - |
dc.contributor.localId | A05491 | - |
dc.contributor.localId | A02796 | - |
dc.relation.journalcode | J00722 | - |
dc.identifier.eissn | 1463-1326 | - |
dc.identifier.pmid | 35229427 | - |
dc.identifier.url | https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14679 | - |
dc.subject.keyword | DPP-4 inhibitor | - |
dc.subject.keyword | antidiabetic drug | - |
dc.subject.keyword | randomized trial | - |
dc.subject.keyword | type 2 diabetes. | - |
dc.contributor.alternativeName | Lee, Minyoung | - |
dc.contributor.affiliatedAuthor | 이민영 | - |
dc.contributor.affiliatedAuthor | 이병완 | - |
dc.citation.volume | 24 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1105 | - |
dc.citation.endPage | 1113 | - |
dc.identifier.bibliographicCitation | DIABETES OBESITY & METABOLISM, Vol.24(6) : 1105-1113, 2022-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.